Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.79 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21496409 | 0.88 | CRBN (1.00) | CRBNBACE1 | |
| Hydrochloric Acid SCHEMBL21496432 | 0.86 | CRBN (0.96) | CRBNBACE1 | |
| SCHEMBL278215 | 0.79 | CRBN (0.50) | CRBNOR51E2FKBP5 | |
| SCHEMBL278367 | 0.79 | CRBN (0.50) | CRBNOR51E2FKBP5 | |
| SCHEMBL5393521 | 0.78 | CRBN (0.68) | CRBNBACE1 | |
| SCHEMBL29749828 | 0.78 | CRBN (0.52) | CRBNBACE1 | |
| SCHEMBL277887 | 0.77 | CRBN (0.48) | CRBNOR51E2FKBP5 | |
| SCHEMBL278221 | 0.77 | CRBN (0.48) | CRBNOR51E2FKBP5 | |
| SCHEMBL277992 | 0.77 | CRBN (0.48) | CRBNOR51E2FKBP5 | |
| Hydrochloric Acid SCHEMBL23067561 | 0.76 | CRBN (0.66) | CRBNBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| WO-2024150815-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | 田辺三菱製薬株式会社 | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | CRBN 1/4885OR51E2 110/4885FKBP5 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.